Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study (XXS)

August 4, 2011 updated by: University Hospital Tuebingen

Xpert Stent Versus Balloon Angioplasty in Complex Lesions of Small Arteries Below the Knee

This study is an investigator-initiated study. The study will be performed as a prospective, randomized, controlled multi-center trial to evaluate the safety and efficiency of Xpert stents compared to PTA in patients with chronic distal artery occlusions or stenosis undergoing catheter revascularization. Patients will be eligible for randomization if they are over 18 years old, if they undergo percutaneous catheter revascularization of an artery below the knee stenosis/occlusion that is less than 15 centimeters in length. Up to two vessels may be treated in this study. All lesions greater than 50% in the below the knee artery region have to be treated either with PTA or stenting according to the randomization.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

180

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • BW
      • Tuebingen, BW, Germany, 72076
        • Recruiting
        • Universtiy of Tuebingen
        • Contact:
        • Sub-Investigator:
          • Thomas Zeller, MD
        • Sub-Investigator:
          • Dierk Scheinert, MD
        • Sub-Investigator:
          • Marc Bosiers, MD
        • Sub-Investigator:
          • Gerhard Rümenapf, MD
        • Sub-Investigator:
          • Johannes Lammer, MD
        • Sub-Investigator:
          • Ernst Pilger, MD
        • Sub-Investigator:
          • Werner Jaschke, MD
        • Sub-Investigator:
          • Dammis Vrougindeweij, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Clinical:

1. Age between 18 and 95 years. 2. Subject or subject's legal representative have been informed of the nature of the study, and have signed the patient informed consent form. Patient is willing to take part in the follow-up protocol of the XXS study.

3. Rutherford stage 4 and 5 Anatomical:

  1. Additional lesions inflow lesions might be successfully treated before randomization and treatment of the target lesion. The inflow lesions which were treated before randomization should only be classified TASC A or B. (TASC= Trans Atlantic Intersociety Conference)
  2. Target vessel with documented run-off to the foot distally of the index lesion with patent plantar arteries
  3. Reference vessel diameter of the target lesion should be ≥ 2 and ≤ 5 mm.
  4. Maximum treated length in the target vessel is 15 cm (might also be divided up into multiple segments with up to 3 different lesions being treated).
  5. Maximum of treated vessels per leg below the knee: 2 (all treated vessels should be treated within the randomization to the study group [PTA or stenting]).
  6. Minimum distance target lesion to talus is 5 cm.

Exclusion Criteria:

  • Clinical

    1. Life expectancy due to a non-atheroslerotic disease less than 12 months.
    2. Previous bypass surgery < 30 days prior to the study procedure.
    3. Known allergies or sensitivities to heparin, contrast media, aspirin, clopidogrel, and nitinol which cannot be treated with antihistamines.
    4. eGFR less than 29 mL/min/1.73m2 (K-DOQI Class 4 and 5) in patients which are not currently treated with dialysis (equivalent to a serum creatinine level of 2.4 mg/dL in a 70 year old male patient)
    5. Subject with breast feeding plans, or child bearing potential with no birth control.
    6. Subjects enrolled in another study concerning the index vessel(s) within 3 months prior to the study procedure.
    7. Untreatable bleeding diatheses.
    8. Patients who have an indication of being treated with coumadin after the intervention.
    9. Inability to ambulate
    10. Hypercoagulable state
    11. Patients with age <18 years and patients who are not able to sign the informed consent form

Anatomical:

  1. Inflow is obstructed and cannot be successfully treated prior to randomization and treatment of below the knee arteries.
  2. Acute thrombus present in the target limb.
  3. Previously implanted stent in the target vessel(s).
  4. Aneurysms in the index leg.
  5. Index vessel with no documented run-up to the foot (please also see inclusion criteria, anatomical).
  6. Inability to use femoral access
  7. No patent pedal arteries

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MLD at the target lesion assessed by angiography
Time Frame: after 12 +/-2 months
treatment effect dependent if stent of PTA was choosen
after 12 +/-2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1. Interventional success rate. Interventional success is defined as restenosis less than 50%. 2. Late lumen loss (LLL)
Time Frame: after 1, 6, 12 months and 3 years
treatment effect dependent on the PTA vs. Stent
after 1, 6, 12 months and 3 years
3. Binary restenosis
Time Frame: arter 6, 12 months and 3 years
Treament effect in long-term
arter 6, 12 months and 3 years
4. Number of patients initially randomized to the PTA group, but receiving stents because of the suboptimal interventional success.
Time Frame: intervention
success rate of PTA only
intervention
Target lesion revascularization, clinical stage, hospital days
Time Frame: after 1, 6, 12 months, and 3 years
treatment effect dependet if patients received stents or PTA only
after 1, 6, 12 months, and 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gunnar Tepe, MD, University Hospital Tuebingen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2007

Primary Completion (Anticipated)

March 1, 2012

Study Completion (Anticipated)

June 1, 2014

Study Registration Dates

First Submitted

October 17, 2007

First Submitted That Met QC Criteria

October 17, 2007

First Posted (Estimate)

October 19, 2007

Study Record Updates

Last Update Posted (Estimate)

August 8, 2011

Last Update Submitted That Met QC Criteria

August 4, 2011

Last Verified

October 1, 2007

More Information

Terms related to this study

Other Study ID Numbers

  • XXS

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe